WHO Grants EUL For Novavax's Updated Protein-based COVID-19 Vaccine

(RTTNews) - Novavax, Inc. (NVAX) on Tuesday said its updated protein-based COVID-19 vaccine NVX-CoV2601 has been granted Emergency Use Listing (EUL) by the World Health Organization. NVX-CoV2601 is an updated version of Novavax's COVID-19 vaccine NVX-CoV2373, formulated to target the Omicron XBB.1.5 subvariant.

The EUL was based on non-clinical data showing that Novavax's COVID-19 vaccine induced functional immune responses against XBB.1.5, XBB.1.16 and XBB.2.3 variants.

The vaccine is also authorized in the U.S. and the European Union, and is under review in other markets.